Immune-Mediated Adverse Events Associated with Ipilimumab CTLA-4 Blockade Therapy: The Underlying Mechanisms and Clinical Management

Por Tarhini, Ahmad
Publicado em 2013

CTLA-4 blockade: therapeutic potential in cancer treatments

Por Tarhini, Ahmad A, Iqbal, Fatima
Publicado em 2010

Anticancer Cytokines: Biology and Clinical Effects of IFN-α2, IL-2, IL-15, IL-21, and IL-12

Por Floros, Theofanis, Tarhini, Ahmad A.
Publicado no Semin Oncol (2015)

Clinical and Immunologic Basis of Interferon Therapy in Melanoma

Por Tarhini, Ahmad A., Kirkwood, John M.
Publicado em 2009

Releasing the Brake on the Immune System: Ipilimumab in Melanoma and Other Tumors

Por Tarhini, Ahmad, Lo, Ernest, Minor, David R.
Publicado em 2010

Adjuvant Therapy: Melanoma

Por Davar, Diwakar, Tarhini, Ahmad, Kirkwood, John M.
Publicado em 2011

Adjuvant Immunotherapy of Melanoma, and Development of New Approaches Using the Neo- Adjuvant Approach in Melanoma

Por Kirkwood, John M., Davar, Diwakar, Tarhini, Ahmad
Publicado em 2013

Adjuvant Therapy for Melanoma

Por Davar, Diwakar, Tarhini, Ahmad A., Kirkwood, John M.
Publicado em 2012

IFN-α in the Treatment of Melanoma

Por Tarhini, Ahmad A., Gogas, Helen, Kirkwood, John M.
Publicado no J Immunol (2012)

Immune Checkpoint Blockade and Interferon-α in Melanoma

Por Rafique, Imran, Kirkwood, John M, Tarhini, Ahmad A
Publicado no Semin Oncol (2015)

Impact of annual hospital volume of high dose interleukin-2 infusions on in-patient mortality in patients with melanoma and renal cell carcinoma

Por Mehta, Kathan, Appleman, Leonard, Wang, Hong, Tarhini, Ahmad, Parikh, Rahul
Publicado no J Immunother Cancer (2015)

Prognostic Significance of Serum S100B Protein in High-Risk Surgically Resected Melanoma Patients Participating in Intergroup Trial ECOG 1694

Por Tarhini, Ahmad A., Stuckert, Joseph, Lee, Sandra, Sander, Cindy, Kirkwood, John M.
Publicado em 2009

Annual Hospital Volume of High Dose Interleukin-2 and Inpatient Mortality in Melanoma and Renal Cell Carcinoma Patients

Por Mehta, Kathan, Appleman, Leonard, Wang, Hong, Tarhini, Ahmad A., Parikh, Rahul A.
Publicado no PLoS One (2016)

Immunotherapy of Cancer in 2012

Por Kirkwood, John M., Butterfield, Lisa H., Tarhini, Ahmad A., Zarour, Hassane, Kalinski, Pawel, Ferrone, Soldano
Publicado em 2012

CD8+ T cell responses in metastatic melanoma patients receiving an adenovirally antigen engineered dendritic cell vaccine +/- IFN-α

Por Du, Samuel, Santos, Patricia M, Tawbi, Hussein, Tarhini, Ahmad, Kirkwood, John M, Butterfield, Lisa H
Publicado no J Immunother Cancer (2015)

Differing Patterns of Circulating Regulatory T-Cells and Myeloid Derived Suppressor Cells in Metastatic Melanoma Patients Receiving Anti-CTLA4 Antibody and Interferon-α or TLR-9 Ag...

Por Tarhini, Ahmad A, Butterfield, Lisa H., Shuai, Yongli, Gooding, William E., Kalinski, Pawel, Kirkwood, John M
Publicado em 2012

Serologic evidence of autoimmunity in E2696 and E1694 patients with high-risk melanoma treated with adjuvant interferon alfa

Por Tarhini, Ahmad A., Shin, Donghoon, Lee, Sandra J., Stuckert, Joseph, Sander, Cindy A., Kirkwood, John M.
Publicado no Melanoma Res (2014)

Phenotypic and functional testing of circulating regulatory T cells in advanced melanoma patients treated with neoadjuvant ipilimumab

Por Retseck, Janet, VanderWeele, Robert, Lin, Hui-Min, Lin, Yan, Butterfield, Lisa H., Tarhini, Ahmad A.
Publicado no J Immunother Cancer (2016)

Melanoma antigen-specific effector T cell cytokine secretion patterns in patients treated with ipilimumab

Por Najjar, Yana G., Ding, Fei, Lin, Yan, VanderWeele, Robert, Butterfield, Lisa H., Tarhini, Ahmad A.
Publicado no J Transl Med (2017)

Surviving with Lung Cancer: Medication-Taking and Oral Targeted Therapy

Por WICKERSHAM, Karen E., HAPP, Mary Beth, BENDER, Catherine M., ENGBERG, Sandra J., TARHINI, Ahmad, ERLEN, Judith A.
Publicado em 2014